Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study

SMART diabetes: the way to go (Safe and Multifactorial Approach to reduce the Risk for Therapy in diabetes)

“…Thus, diverse approaches to personalize therapy have been proposed [2], and a recent joint ADA/EASD position statement suggest to personalizing the glycaemic target on the basis of patients' features [3]. However, few data are available about the feasibility, and the effectiveness of personalized therapies for T2D [4] and new trials testing patient-tailored approaches are claimed to drive clinicians in the pitfalls of the available Evidence-Based Medicine (EBM). In the face of existing limitations, we propose some evergreen landmarks to correctly tailor therapies in subjects with type 2 diabetes.…”

Linagliptin is associated to increased treatment adherence and satisfaction in elderly outpatients with diabetes and advanced chronic kidney disease

“…Due to their favorable safety profile, especially in terms of reduced hypoglycemia, DPP-4 inhibitors are pro bably the only oral glucose-lowering agents for which some evidence from dedicated randomized clinical trials in patients aged ≥65 years and/or with moderate to severe renal impairment has been published over the last few years. 3,19,[32][33][34][35][36][37][38][39][40] One of these studies, a randomized, placebocontrolled trial in 133 patients with type 2 diabetes (HbA1c 7%-10%) and severe renal impairment (eGFR <30 mL/min per 1.73 m 2 ) showed that adding linagliptin (5 mg/day) to existing background therapy resulted in a significantly greater reduction of HbA1c at 12 weeks 36 which was maintained at 1 year (P<0.0001 vs baseline). In linagliptin-treated patients the incidence of adverse events and severe hypoglycemia was similar to the placebo group.…”

Características diferenciales de la diabetes mellitus tipo 2 en el paciente anciano. Papel de los inhibidores de la dipeptidil peptidasa 4

“…Disponemos ya de estudios en personas mayores de todos ellos que apoyan su eficacia hipoglicemiante y seguridad [67][68][69][70][71][72][73] . Tres de estos estudios se realizaron en pacientes con 70 o más años de edad 67,68,73 .…”

“…La conclusión de este estudio es que la eficacia y seguridad de vildagliptina en sujetos ≥75 años es similar a la de los pacientes más jóvenes. Strain et al 73 (estudio INTERVAL), realizaron un ensayo doble ciego en pacientes ≥70 años con DM2 mal controlada, sin tratamiento previo o con antidiabéticos orales (se excluyeron pacientes tratados con arGLP1 o insulina). Los pacientes fueron aleatorizados a recibir durante 24 semanas vildagliptina 50 mg cada12 horas (n: 139) o placebo (n: 137).…”